Abera develops vaccine candidates based its technology – BERA. The main candidate is a universal pneumococcal vaccine candidate and the company explores applications in immunotherapy.
Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to efficient vaccine candidates.
Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experience to create innovative vaccines.
Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to create efficient vaccine candidates.
Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experiences into new, innovative vaccines.
Sammanfattning av bokslutskommuniké för 2022. FINANSIELL ÖVERSIKT HELÅRET 2022 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 1 850 (1 190) kSEK
Abera Bioscience AB (“Abera” or the “Company”) announces that the toxicological studies for the universal pneumococcus vaccine candidate, Ab-01.12, is initiated which is an important
Carlsquare Equity Research inleder bevakning av vaccinbolaget Abera Bioscience AB (”Abera” eller ”Bolaget”) och publicerar idag en initieringsanalys på bolaget. Analysen kan laddas ner och läsas